# A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

> **NCT04623996** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Anemia in Myelodysplastic Syndromes

## Interventions

- **DRUG:** TP-0184

## Key facts

- **NCT ID:** NCT04623996
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-28
- **Primary completion:** 2021-04-27
- **Final completion:** 2021-04-27
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to limitations imposed by the COVID pandemic and the competitive landscape for myelodysplastic syndrome, this study was unable to enroll a sufficient patient population.
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623996, "A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04623996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*